Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia and a diagnostic test to determine which AML patients would most likely benefit from this treatment.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Researchers caution that expediting HLH treatment may miss underlying cancers

Physicians who specialize in a devastating and aggressive immune disorder called hemophagocytic lymphohistiocytosis report in a new study that extra care should be taken to ensure an HLH diagnosis doesn't obscure possible underlying cancers.

1 Oct 2018

Researchers design new combination therapy for reducing NSCLC cell growth

Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.

29 Sep 2018

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.

27 Sep 2018

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents, which stimulate the body to produce red blood cells, according to a dissertation at Sahlgrenska Academy, Sweden.

24 Sep 2018

Drug combination targets pre-leukemia stem cells

Your body's blood cells are manufactured by hematopoietic stem cells in bone marrow. But just as regular, mature cells can become cancerous, so too can stem cells.

12 Sep 2018

Scientists develop first DNA-based test for predicting risk of leukemia relapse

A group of Canadian and Korean scientists and physicians have developed the first DNA-based test that allows them to tell which patients will relapse after receiving chemotherapy and a bone marrow transplant, for their acute myeloid leukemia, or AML.

11 Sep 2018

Researchers identify new cancerous cells responsible for acute myeloid leukemia relapse

McMaster University researchers have provided evidence of new cancerous cells they have termed cancer regenerating cells, which are responsible for the return of acute myeloid leukemia after remission.

10 Sep 2018

HU researchers develop new biological drug that may cure acute myeloid leukemia

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefited from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.

24 Aug 2018

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

20 Aug 2018

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

A new study provides insights into the degree to which socioeconomic status explains racial and ethnic disparities in childhood cancer survival.

20 Aug 2018

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials

When enrolled in a cancer clinical trial, the differences in survival rates between rural and urban patients are significantly reduced, SWOG study results show.

17 Aug 2018

Study provides new insight into how 'trash bag of the cell' traps and seals off waste

The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, much like a trash bag.

16 Aug 2018

Study reveals role of RUNX proteins in DNA repair

A study by researchers from the Cancer Science Institute of Singapore at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia pathway.

15 Aug 2018

Scientists identify stress hormone as key factor in failure of immune system to inhibit leukemia

The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.

14 Aug 2018

New discovery could pave way for improved leukemia treatment

Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukemia patients possess this favorable mutation, but until now, how it helps improve outcomes has remained unknown.

9 Aug 2018

Combination of arsenic and existing leukemia drug may combat cancer

Investigators have discovered that arsenic in combination with an existing leukemia drug work together to target a master cancer regulator.